The project will dissect the biological basis of intrinsic tumour aggressiveness through a novel "born to be bad" (BBB) versus "born to be good" (BBG) biological framework. BBB tumours are micrometastatic from the very beginning, persist as minimal residual disease (MRD) after surgery, and spread early. Conversely, BBG tumours remain localized and are cured by surgery alone. No clinical biomarker currently distinguishes these phenotypes, and patients are often treated the same way.